ANI Pharmaceuticals Inc
WKN: A1W15D / ISIN: US00182C1036Biosante - Potential zum Tenbagger??
| eröffnet am: | 14.02.12 02:47 von: | Vollzeittrader |
| neuester Beitrag: | 24.04.21 23:25 von: | Utarxcwa |
| Anzahl Beiträge: | 572 | |
| Leser gesamt: | 83835 | |
| davon Heute: | 113 | |
bewertet mit 5 Sternen |
||
|
|
||
21.02.12 17:45
#201
BoersenhundRE
max; du hast sichelich einen anderen Chart
... aber keine Zündkerze, nicht das wir uns falsch verstehen....
21.02.12 17:52
#203
max06
Du kannst wohl keinen Chart einstellen?
Hab ich mir gedacht.
Ich kann's auch nicht
Ich kann's auch nicht
21.02.12 17:52
#204
Vollzeittrader
0,83 USD!
Das wäre ne komplette Trendwende! Naja, aber warten wir es ab :P
21.02.12 17:59
#206
BoersenhundRE
vollzeittrader, sie muss ja über 0,83 schliessen
.... ansonsten wir sie nicht weiss!.... Ab Mittag (ja max, in Amerika) geht es hoch!
Lehrling, ich garantiere allerdings für nichts....
Meiner Meinung nach... sind neun (!) schwarze Kerzen hintereinander einfach zu viel, daher dürfte eine zehnte nicht folgen... Das Ding ist überverkauft!
Lehrling, ich garantiere allerdings für nichts....
Meiner Meinung nach... sind neun (!) schwarze Kerzen hintereinander einfach zu viel, daher dürfte eine zehnte nicht folgen... Das Ding ist überverkauft!
21.02.12 18:03
#207
BoersenhundRE
Danke, falke...
Sehr aufmerksam... :-)
Die zehnte Kerze wird erst weiss (bei Falke`s Chart grün) wenn der SK über den EK (heute 83)
liegt.
Die zehnte Kerze wird erst weiss (bei Falke`s Chart grün) wenn der SK über den EK (heute 83)
liegt.
21.02.12 18:08
#208
max06
Und morgen erzählst du uns die 11
Kerze wird weiß .
Und selbst wenn, kann ja die 12te wieder schwarz werden
Und selbst wenn, kann ja die 12te wieder schwarz werden
21.02.12 18:12
#209
koolram
@ Boersenhund
Interessante Theorie bzgl den Kerzen.
Ich hoffe Du hast recht.
Ich gehe eher nach MA Linien und die werden sich bald kreuzen.
Somit sollte/koennte/muesste der chart Richtung Norden gehen.
Bei dieser Aktie ist nur leider alles moeglich.
Die laeuft ziemlich komisch.
Ich hoffe Du hast recht.
Ich gehe eher nach MA Linien und die werden sich bald kreuzen.
Somit sollte/koennte/muesste der chart Richtung Norden gehen.
Bei dieser Aktie ist nur leider alles moeglich.
Die laeuft ziemlich komisch.
21.02.12 18:13
#210
falke2
@max06
warum so verbissen ?
10 grüne-kerzen und wir sind über 2$ ;-)))
servu$
10 grüne-kerzen und wir sind über 2$ ;-)))
servu$
21.02.12 18:34
#211
Vollzeittrader
Löschung
Moderation
Zeitpunkt: 22.02.12 09:49
Aktion: Löschung des Beitrages
Kommentar: Werbung - threadfremd
Zeitpunkt: 22.02.12 09:49
Aktion: Löschung des Beitrages
Kommentar: Werbung - threadfremd
21.02.12 18:58
#213
BoersenhundRE
vollzeittrader... alle schlecht gelaunt
.... aber mir bekommst du keinen. :P
21.02.12 19:12
#214
Vollzeittrader
Ich merk das schon...
aber Leute, mal ganz ehrlich: Locker bleiben...
Solange Biosante gelistet bleibt, ist nichts los... eine gute Nachricht aus der pipeline, dann stehen wir hier nicht mehr unter 1,00 $!
Weiß jemand zufällig die Frist, wielange Biosante noch bleibt für Listing??
21.02.12 19:33
#216
falke2
@Vollzeittrader
hast doch gerade selber geschrieben Locker bleiben... ;-))
der tag ist noch nicht rum ;-))
servu$
der tag ist noch nicht rum ;-))
servu$
21.02.12 19:36
#217
Vollzeittrader
Knapp 170k shares sind grad
übern Tisch gegangen... wer das wohl war...
Wäre nicht das erste mal, dass Biosante abends ins Plus dreht... komische Aktie... =)
21.02.12 20:41
#219
Vollzeittrader
Puhh, die taucht heute echt extrem ab...
Biotechs sind unberechenbar!
21.02.12 21:06
#220
BoersenhundRE
Es verschlägt mir die Sprache...
.. dabei dachte ich .... schlimmer als 0,75 Dollar... wird es nimmer!
und nu?
und nu?
21.02.12 21:09
#221
Vollzeittrader
Ich weiß auch nicht..
Anmelden76... ich glaube, er hatte recht! Seine Posts im Nachbarthread würden das alles erklären! Naja, heute ist der Drop gelutscht!
21.02.12 21:17
#222
falke2
news
servu$
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against BioSante Pharmaceuticals, Inc.
2012-02-21 14:59 ET - News Release
SAN DIEGO -- (Business Wire)
Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) (http://www.rgrdlaw.com/cases/biosante/) today announced that a class action has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of BioSante Pharmaceuticals, Inc. (“BioSante”) (NASDAQ:BPAX) securities during the period between February 8, 2010 and December 15, 2011 (the “Class Period”).
If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from February 6, 2012. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Darren Robbins of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at djr@rgrdlaw.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.rgrdlaw.com/cases/biosante/. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
The complaint charges BioSante and its Chief Executive Officer with violations of the Securities Exchange Act of 1934. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology.
The complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding the commercial viability, effectiveness, and market potential for LibiGel, a drug designed to improve the sex drive of women suffering from female sexual dysfunction, and specifically hypoactive sexual desire disorder (“HSDD”). Defendants boasted about LibiGel’s efficacy over placebo in clinical trials, and provided supposedly concrete “data” regarding the drug’s “statistically significant” effect on increasing the “number of satisfying sexual events” for women suffering from HSDD. As a result of these false statements, BioSante’s stock traded at artificially inflated prices during the Class Period, reaching a high of $3.81 on July 12, 2011.
On December 14, 2011, BioSante issued a press release disclosing for the first time to investors that LibiGel failed to yield positive results in large-scale efficacy tests designed by the Company. According to the clinical trial results, women treated with LibiGel did not experience a statistically significant increase in either total satisfying sexual encounters or sexual desire. In fact, in the double-blind, placebo-controlled trial, LibiGel did not fare significantly better than the placebo. On this news, BioSante’s stock collapsed $1.64 per share to close at $0.48 per share on December 15, 2011, a one-day decline of 77% on volume of nearly 50 million shares.
According to the complaint, the true facts, which were known by the defendants but concealed from the investing public during the Class Period, were as follows: (a) LibiGel’s efficacy was well short of that required to obtain FDA approval; and (b) LibiGel failed to yield statistically superior results to placebo.
Plaintiff seeks to recover damages on behalf of all purchasers of BioSante securities during the Class Period (the “Class”). The plaintiff is represented by Robbins Geller, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.
Robbins Geller, a 180-lawyer firm with offices in San Diego, San Francisco, New York, Boca Raton, Washington, D.C., Philadelphia and Atlanta, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Robbins Geller Web site (http://www.rgrdlaw.com) has more information about the firm.
Contacts:
Robbins Geller Rudman & Dowd LLP
Darren Robbins
800-449-4900 or 619-231-1058
djr@rgrdlaw.com
Source: Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against BioSante Pharmaceuticals, Inc.
2012-02-21 14:59 ET - News Release
SAN DIEGO -- (Business Wire)
Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) (http://www.rgrdlaw.com/cases/biosante/) today announced that a class action has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of BioSante Pharmaceuticals, Inc. (“BioSante”) (NASDAQ:BPAX) securities during the period between February 8, 2010 and December 15, 2011 (the “Class Period”).
If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from February 6, 2012. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Darren Robbins of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at djr@rgrdlaw.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.rgrdlaw.com/cases/biosante/. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
The complaint charges BioSante and its Chief Executive Officer with violations of the Securities Exchange Act of 1934. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology.
The complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding the commercial viability, effectiveness, and market potential for LibiGel, a drug designed to improve the sex drive of women suffering from female sexual dysfunction, and specifically hypoactive sexual desire disorder (“HSDD”). Defendants boasted about LibiGel’s efficacy over placebo in clinical trials, and provided supposedly concrete “data” regarding the drug’s “statistically significant” effect on increasing the “number of satisfying sexual events” for women suffering from HSDD. As a result of these false statements, BioSante’s stock traded at artificially inflated prices during the Class Period, reaching a high of $3.81 on July 12, 2011.
On December 14, 2011, BioSante issued a press release disclosing for the first time to investors that LibiGel failed to yield positive results in large-scale efficacy tests designed by the Company. According to the clinical trial results, women treated with LibiGel did not experience a statistically significant increase in either total satisfying sexual encounters or sexual desire. In fact, in the double-blind, placebo-controlled trial, LibiGel did not fare significantly better than the placebo. On this news, BioSante’s stock collapsed $1.64 per share to close at $0.48 per share on December 15, 2011, a one-day decline of 77% on volume of nearly 50 million shares.
According to the complaint, the true facts, which were known by the defendants but concealed from the investing public during the Class Period, were as follows: (a) LibiGel’s efficacy was well short of that required to obtain FDA approval; and (b) LibiGel failed to yield statistically superior results to placebo.
Plaintiff seeks to recover damages on behalf of all purchasers of BioSante securities during the Class Period (the “Class”). The plaintiff is represented by Robbins Geller, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.
Robbins Geller, a 180-lawyer firm with offices in San Diego, San Francisco, New York, Boca Raton, Washington, D.C., Philadelphia and Atlanta, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Robbins Geller Web site (http://www.rgrdlaw.com) has more information about the firm.
Contacts:
Robbins Geller Rudman & Dowd LLP
Darren Robbins
800-449-4900 or 619-231-1058
djr@rgrdlaw.com
Source: Robbins Geller Rudman & Dowd LLP
21.02.12 21:23
#224
Vollzeittrader
Auweia!
Jungs, ich hoffe ihr hattet SL gesetzt! Wer hätte das gedacht.. nach einer FDA-Zulassung so ein Tauchgang! Übel!
Trotzdem allen noch nen schönen Abend! Hoffe die 0,70 USD halten!!